EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males

Minkyu Choi, Byung Hak Jin, Do Hoon Keum, Kyoung Hoon Mo, Min Soo Park, Juhwan Lee, Sungjin Park, Choon Ok Kim

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1556 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Minkyu Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Donepezil, Memantine, Cholinesterase Inhibitors. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A fixed‐dose combination (FDC) tablet formulation of donepezil/memantine (10/20 mg) was developed to improve medication compliance in patients with Alzheimer's disease (AD). This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of donepezil (10 mg) and memantine (20 mg). In a randomized, open‐label, single‐dose, 2‐way crossover study, 24 healthy Korean participants received a single oral dose of FDC in 1 period and an SC of donepezil and memantine in another period. For PK analysis, blood samples were collected up to 240 hours after administration. The geometric mean ratios and their 90% confidence intervals for the main PK parameters (C max and AUC last ) indicated PK equivalence between the FDC and SC formulations. Regarding the safety profile, all adverse events were mild, with no serious adverse events. These findings support the use of an FDC formulation as a viable alternative to SCs of donepezil and memantine, potentially improving treatment adherence in patients with moderate‐to‐severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DonepezilMemantineCholinesterase InhibitorsHumansMaleTherapeutic EquivalencyCross-Over StudiesTabletsDrug CombinationsAdultRepublic of KoreaHealthy VolunteersArea Under CurveYoung AdultAdministration, Oral

Stichwörter der Autor:innen

Alzheimer's diseasedonepezilfixed‐dose combinationmemantine

Substanzen

DonepezilMemantineTabletsDrug CombinationsCholinesterase Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Pharmaceutical Medicine and Regulatory Sciences, Colleges of Medicine and Pharmacy, Yonsei University, Incheon, South Korea.
  • Department of Pediatrics, Yonsei University College of Medicine, Seoul, South Korea.
  • Department of Clinical Research, Hyundai Pharmaceutical Co. Ltd., Seoul, South Korea.

Zitieren

APA

Choi, M., Jin, B. H., Keum, D. H., Mo, K. H., Park, M. S., Lee, J., Park, S., & Kim, C. O. (2025). Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1556

Vancouver

Choi M, Jin BH, Keum DH, Mo KH, Park MS, Lee J, et al. Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1556

BibTeX
@article{Choi2025,
  author = {Choi, Minkyu and Jin, Byung Hak and Keum, Do Hoon and Mo, Kyoung Hoon and Park, Min Soo and Lee, Juhwan and Park, Sungjin and Kim, Choon Ok},
  title = {Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed‐Dose Combination Versus Single‐Component Tablets in Healthy Korean Males},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1556}
}
Kostenlos starten →